Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImmunoGen, Inc.
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
Interview: Germany’s ITM is executing on its plan to develop targeted radionuclide-based therapies with its lead lutetium-177 product in Phase III trials supported by a just closed $109m financing.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
Henlius has announced plans to seeing its sales shoot up in 2020 based on three new launches.
- Controlled Release
- Site Specific
- Drug Delivery
- Large Molecule